FDA Grants Orphan Drug Designation to IKT-001 for PAH

Inhibikase Therapeutics announced the FDA granted Orphan Drug Designation for its pulmonary arterial hypertension treatment, IKT-001. This benefit includes potential tax credits and market exclusivity.